Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Med Oral Patol Oral Cir Bucal ; 29(3): e441-e450, 2024 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-38615255

RESUMO

BACKGROUND: The present systematic review aims to investigate the guidelines for prescribing Preventive Antibiotic Therapy (PAT) in the placement of dental implants (DIs) without anatomical constraints in healthy patients by clinicians in Europe and to compare them with current recommendations. MATERIAL AND METHODS: A search was performed in 4 databases: Medline (via PubMed), Web of Science, Scopus, and LILACS. The criteria employed were those described in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) declaration (PROSPERO Registration number: CRD42022382278). RESULTS: The electronic search identified 10 studies published between 2010 and 2023 that met the established criteria. Overall, 60.8% ± 24.1% of European professionals routinely prescribe PAT, with the most frequent regimen being perioperative (mean= 46.7% ± 24.3%), followed by postoperative PAT only (mean= 20.3% ± 9.7%). CONCLUSIONS: The most commonly prescribed antibiotic both pre- and postoperatively is amoxicillin and, in allergic patients, clindamycin. In Europe, more doses of PAT are being prescribed than suggested by current recommendations. For this reason, more PAT education is needed in educational curricula to promote a more rational use of antibiotics to reduce the occurrence of antimicrobial resistance.


Assuntos
Antibacterianos , Antibioticoprofilaxia , Implantes Dentários , Europa (Continente) , Humanos , Antibacterianos/uso terapêutico , Padrões de Prática Odontológica/estatística & dados numéricos , Implantação Dentária , Padrões de Prática Médica/estatística & dados numéricos , Guias de Prática Clínica como Assunto
2.
Med Oral Patol Oral Cir Bucal ; 27(6): e588-e599, 2022 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-36173720

RESUMO

BACKGROUND: Currently, the most frequently employed therapies in the treatment of inflammatory bowel diseases (IBD), i.e., Crohn's Disease (CD), Ulcerative Colitis (UC) or unclassified IBD (IBD-U) are monoclonal anti-TNFs and anti-integrin therapies, such as vedolizumab (VDZ). Forty-seven per cent of these patients present extra-intestinal manifestations, the second most prevalent being aphthous stomatitis (AS). The present study aims to investigate which of the two therapies is associated with a lower prevalence of AS after treatment. MATERIAL AND METHODS: An electronic search of the MEDLINE (via PubMed), Web of Science, SCOPUS, LILACS and OpenGrey databases was carried out. The criteria used were those described by the PRISMA Statement. The search was not temporarily restricted and was updated to January 2022. The quality assessment was analyzed using the JBI Prevalence Critical Appraisal Tool. RESULTS: After searching, 7 studies were included that met the established criteria. Of these, 6 analysed the prevalence of AS in CD patients and 4 in UC. A total of 1,744 patients were analysed (CD=1,477 patients; 84.69%; UC=267; 15.31%). The greatest reduction in AS prevalence was observed after anti-TNF therapy. The effect of these therapies on the prevalence of AS in patients with IBD-U could not be determined. CONCLUSIONS: Both biologic therapies achieve a reduction in the prevalence of AS in IBD patients (CD and UC). However, the best results were obtained in patients treated with anti-TNFs, possibly because VDZ is often used in patients who do not respond adequately to previous treatment with anti-TNFs and because of its intestinal specificity.


Assuntos
Colite Ulcerativa , Doença de Crohn , Doenças Inflamatórias Intestinais , Estomatite Aftosa , Humanos , Inibidores do Fator de Necrose Tumoral , Anticorpos Monoclonais/uso terapêutico , Prevalência , Doenças Inflamatórias Intestinais/tratamento farmacológico , Doenças Inflamatórias Intestinais/epidemiologia , Colite Ulcerativa/epidemiologia , Doença de Crohn/epidemiologia
3.
Public Health ; 155: 26-34, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29304473

RESUMO

OBJECTIVES: Obesity is one of the most prevalent chronic pathologies in the world and has become a public health problem. At the present time, bariatric surgery (BS) is considered the best option and the only effective method of treatment, but it can occasionally result in a series of alterations at the oral level. This study aims to review the current literature to establish the possible association of patients who have undergone BS and a greater risk of dental caries. STUDY DESIGN: This study is a systematic review of the literature. METHODS: A search was made in the database of Medline (via PubMed), over the last 10 years, using the keywords 'bariatric surgery' OR 'gastrectomy' OR 'obesity surgery,' combined independently with the terms 'saliva' and 'dental caries' by means of the connector 'AND.' The criteria used were those described in the PRISMA® Declaration for performing systematic reviews. Inclusion criteria and study selection: (a) studies done with humans; (b) articles published in English and Spanish; (c) series of cases; and (d) clinical trials. The risk of bias was assessed independently by two authors. In both data extraction and risk of bias assessment, disagreements were resolved through discussion with a third author. RESULTS: Two independent reviewers read the titles and summaries of the 79 articles found. Finally, nine of them were included in the study. In the various articles, the parameters that had clinical relevance to the risk of dental caries were evaluated. CONCLUSIONS: Within the limitations of this study, it is plausible to think that patients who have undergone BS have a greater risk of dental caries. The oral complications associated with BS could be prevented or minimized by including in the multidisciplinary treatment of these patients a team of odontologists who would be responsible for prevention and oral assessment.


Assuntos
Cirurgia Bariátrica/efeitos adversos , Cárie Dentária/epidemiologia , Obesidade/cirurgia , Humanos , Fatores de Risco
4.
J Hosp Infect ; 113: 30-43, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-33865974

RESUMO

Angiotensin converting enzyme 2 (ACE2) is the cellular receptor for SARS-CoV-2, so ACE2-expressing cells can act as target cells and are susceptible to infection. ACE2 receptors are highly expressed in the oral cavity, so this may be a potential high-risk route for SARS-CoV-2 infection. Furthermore, the virus can be detected in saliva, even before COVID-19 symptoms appear, with the consequent high risk of virus transmission in asymptomatic/presymptomatic patients. Reducing oral viral load could lead to a lower risk of transmission via salivary droplets or aerosols and therefore contribute to the control of the pandemic. Our aim was to evaluate the available evidence testing the in-vitro and in-vivo effects of oral antiseptics to inactivate or eradicate coronaviruses. The criteria used were those described in the PRISMA declaration for performing systematic reviews. An electronic search was conducted in Medline (via PubMed) and in Web of Sciences, using the MeSH terms: 'mouthwash' OR 'oral rinse' OR 'mouth rinse' OR 'povidone iodine' OR 'hydrogen peroxide' OR 'cetylpyridinium chloride' AND 'COVID-19' OR 'SARS-CoV-2' OR 'coronavirus' OR 'SARS' OR 'MERS'. The initial search strategy identified 619 articles on two electronic databases. Seventeen articles were included assessing the virucidal efficacy of oral antiseptics against coronaviruses. In conclusion, there is sufficient in-vitro evidence to support the use of antiseptics to potentially reduce the viral load of SARS-CoV-2 and other coronaviruses. However, in-vivo evidence for most oral antiseptics is limited. Randomized clinical trials with a control group are needed to demonstrate its clinical efficacy.


Assuntos
Anti-Infecciosos Locais/farmacologia , Tratamento Farmacológico da COVID-19 , Antissépticos Bucais/farmacologia , Carga Viral/efeitos dos fármacos , Cetilpiridínio/farmacologia , Humanos , Peróxido de Hidrogênio/farmacologia , Boca , Pandemias , Povidona-Iodo/farmacologia , SARS-CoV-2/efeitos dos fármacos , Saliva/virologia
5.
Br Dent J ; 221(10): 645-649, 2016 Nov 18.
Artigo em Inglês | MEDLINE | ID: mdl-27857102

RESUMO

Introduction The complications associated with dental implants are numerous, most of them of an inflammatory nature; nevertheless, some isolated cases of oral squamous cell carcinoma (OSCC) have been found in the vicinity of the implants. The objective of the present article is to know whether there is an association between dental implants and the development of OSCC.Method and materials A search was carried out in Medline, Tripdatabase and Cochrane with the keywords 'dental implants' AND 'squamous cell carcinoma', and 'dental implant complications' AND 'squamous cell carcinoma.' The criteria for inclusion were articles published in English that dealt with the possible carcinogenic effects of implants and the possible malign transformation of oral lesions after the insertion of the implants. For the analysis, cases were used in which an OSCC had appeared in the peri-implantary mucosa.Results After an initial search, 269 articles were selected, of which 197 were excluded as not being directly related to the subject. Finally, 45 articles were selected, with 23 of them being used in the analysis. In these, 46 cases of OSCC in the vicinity of implants were discussed.Discussion Chronic inflammation in itself can lead to a malign transformation of the oral tissue, while in other cases it is caused and modulated by carcinogens, genetic factors or inherent factors in the patient, or by the dental implants.Conclusions It is not possible to establish a cause-effect relation between the implants and the development of OSCC. Its presence can be confused with peri-implantitis, so that in the cases where it appears suddenly, does not respond to conventional treatment and/or there is anaesthesia or paresthesia, it is advisable to do a biopsy. It is important to make an adequate selection of the patient and reduce or eliminate the risk factors. The findings of the present review are based on case study level of evidence, so meta-analysis is needed to further draw from these results.


Assuntos
Carcinoma de Células Escamosas/etiologia , Implantes Dentários/efeitos adversos , Neoplasias Bucais/etiologia , Humanos , Inflamação , Peri-Implantite , Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA